Apoptotic activity of alpha-mangostin in acetaldehyde- induced LX2 hepatic stellate cell lines

Lestari, Novriantika; Amartya, Daniel; Soetikno, Vivian; Louisa, Melva

doi:10.1063/1.5139356

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primers used β-actin, Ki-67, c-Jun, Bax, Bcl-2, Caspase-3 and Caspase-9, GPx and MnSOD were as described previously. [15][16][17] The number of cDNA templates used for each sample was 100 ng. Cycle threshold (Ct) was measured automatically using the software.…”

Section: Analysis Of Mrna Expressions Using Qrt-pcrmentioning

confidence: 99%

Alpha-Mangostin Enhances Proliferation in Sorafenib-Surviving HepG2 Liver Cancer Cells by Increasing Anti-Apoptosis and Antioxidant Markers Expressions

Louisa¹,

Annisa²,

Basuki³

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Sorafenib is the first-line systemic option for treatment in advanced liver cancer. However, sorafenib resistance may develop rapidly, which may involve apoptosis and oxidative stress dysregulations. Several alternative treatments have been suggested to alleviate the delayed resistance of cancer cells to sorafenib, including alpha mangostin (AM). According to an earlier study, AM might be able to overcome doxorubicin resistance in hepatocellular cancer cells. Objective: The aim of this study was to investigate the effects of AM in sorafenib-surviving HepG2 cells, a hepatocellular carcinoma (HCC) cell line. Methods: Sorafenib 10 µM was used to treat HepG2 to obtain sorafenib-surviving cells. Subsequently, sorafenib surviving cells were treated with DMSO -(vehicle) or sorafenib (SF) 10 µM or AM 20 µM, or SF 10 µM + AM 20 µM. Afterward, the cells were counted, collected and extracted for RNA. The mRNA expressions of Ki-67, c-Jun, Bcl-2, Bax, Caspase-3 and -9, GPx, and MnSOD were then quantified using qRT-PCR. Results: Treatment of alpha-mangostin, alone or in combination with sorafenib combined enhanced the expressions of proliferation markers, Ki-67 and c-Jun. In addition, there was a marked increase in mRNA expressions of Bax and BCl2, but not Caspase-3 and -9. There were amplifications of antioxidant markers expressions, GPx, and MnSOD after AM or a combination of sorafenib and AM. Conclusion: Treatment of alpha mangostin in sorafenib-surviving HCC cells caused an increase in proliferation markers, which might be explained by the reduced expressions of apoptosis markers and enhancement of antioxidant markers.

show abstract

Section: Analysis Of Mrna Expressions Using Qrt-pcrmentioning

confidence: 99%